Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nilotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 16/20 | 0.97 |
| ▸ | BCR known ✓ | P11274 | 8/20 | 0.97 |
| ▸ | KIT | P10721 | 11/20 | 0.97 |
| ▸ | LDLR | P01130 | 8/20 | 0.97 |
| ▸ | PCSK9 | Q8NBP7 | 8/20 | 0.97 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.97 |
| ▸ | LCK | P06239 | 4/20 | 0.97 |
| ▸ | LYN | P07948 | 4/20 | 0.97 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.97 |
| ▸ | FLT3 | P36888 | 4/20 | 0.97 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.97 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.97 |
| ▸ | SRC | P12931 | 2/20 | 0.97 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.97 |
| ▸ | CA12 | O43570 | 1/20 | 0.97 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.97 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.97 |
| ▸ | STK10 | O94804 | 1/20 | 0.97 |
| ▸ | CA1 | P00915 | 1/20 | 0.97 |
| ▸ | CA2 | P00918 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nilotinib SCHEMBL1460791 | 1.00 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL30715492 | 1.00 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL29392981 | 1.00 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL29693815 | 1.00 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL30715493 | 1.00 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL28663798 | 1.00 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL2223849 | 1.00 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL18095566 | 1.00 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL1459790 | 0.99 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL1984397 | 0.99 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 773 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4355306-B1 | GRANULATE COMPOSITION COMPRISING NILOTINIB | HELM PHARMACEUTICALS GMBH (DE) | 2026-01-21 | — | — | EP | claimed |
| EP-4599048-A1 | COMPOSITIONS AND METHODS FOR SMALL MOLECULE BASED EXPANSION OF PLURIPOTENT STEM CELLS | Trailhead Biosystems Inc. (US) | 2025-08-13 | — | — | EP | claimed |
| EP-4569090-A2 | METHODS AND COMPOSITIONS FOR GENERATING OLIGODENDROCYTE PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-06-18 | — | — | EP | claimed |
| EP-3893913-B1 | TRANSFERRIN RECEPTOR TARGETING PEPTIDES | FRED HUTCHINSON CANCER CENTER (US) | 2025-03-26 | — | — | EP | claimed |
| CN-119654404-A | Methods and compositions for producing oligodendrocyte progenitor cells | 特雷尔赫德生物系统股份有限公司 | 2025-03-18 | — | — | CN | claimed |
| US-20240316044-A1 | GRANULATE COMPOSITION COMPRISING NILOTINIB | HELM AG (DE) | 2024-09-26 | — | — | US | claimed |
| US-12029740-B2 | Amorphous nilotinib microparticles and uses thereof | NANOCOPOEIA, LLC (US) | 2024-07-09 | — | — | US | claimed |
| US-12016861-B2 | Amorphous nilotinib microparticles and uses thereof | NANOCOPOEIA, LLC (US) | 2024-06-25 | — | — | US | claimed |
| US-20240203601-A1 | ANALYZING COPY NUMBER VARIATION IN THE DETECTION OF CANCER | VERINATA HEALTH, INC. | 2024-06-20 | — | — | US | claimed |
| US-11998548-B2 | Amorphous nilotinib microparticles and uses thereof | NANOCOPOEIA, LLC (US) | 2024-06-04 | — | — | US | claimed |
| US-8039290-B2 | Method of making photovoltaic cell | GENERAL ELECTRIC COMPANY (US) | 2011-10-18 | — | — | US | claimed |
| WO-2011086541-A1 | NOVEL POLYMORPH OF NILOTINIB MONOHYDROCHLORIDE MONOHYDRATE | GENERICS [UK] LIMITED (GB) | 2011-07-21 | — | — | WO | claimed |
| EP-1910336-B1 | MONOHYDROCHLORIDE MONOHYDRATE SALT OF 4-METHYL-N-[3-(4-METHYL-IMIDAZOL-1-YL)-5-TRIFLUOROMETHYL-PHENYL]-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-BENZAMIDE | NOVARTIS AG (CH) | 2011-06-29 | — | — | EP | claimed |
| EP-2186808-A1 | Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide | Novartis AG (CH) | 2010-05-19 | — | — | EP | claimed |
| US-20100087463-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NILOTINIB OR ITS SALT | NOVARTIS AG (CH) | 2010-04-08 | — | — | US | claimed |
| CN-101516344-A | Pharmaceutical composition comprising nilotinib or a salt thereof | NOVARTIS AG (CH) | 2009-08-26 | — | — | CN | claimed |
| EP-2068839-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING NILOTINIB OR ITS SALT | Novartis AG (CH) | 2009-06-17 | — | — | EP | claimed |
| US-20080200487-A1 | Salts of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide | NOVARTIS AG (CH) | 2008-08-21 | — | — | US | claimed |
| EP-1923053-A1 | Pharmaceutical compositions comprising nilotinib or its salt | Novartis AG (CH) | 2008-05-21 | — | — | EP | claimed |
| WO-2008037716-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING NILOTINIB OR ITS SALT | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316044-A1 | GRANULATE COMPOSITION COMPRISING NILOTINIB | ABL1, GRN, TP53 | ABL1 1/4885BCR 111/4885KIT 576/4885 |
| US-12016861-B2 | Amorphous nilotinib microparticles and uses thereof | ABL1, CDKN1A, CDK2 | ABL1 1/4885BCR 173/4885KIT 246/4885 |
| US-20100087463-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NILOTINIB OR ITS SALT | ABL1, JAK1, STAT5A | ABL1 1/4885BCR 80/4885KIT 64/4885 |
| US-20080200487-A1 | Salts of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide | AZI2, BRD4, BRD3 | ABL1 12/4885BCR 2700/4885KIT 1164/4885 |
| US-12029740-B2 | Amorphous nilotinib microparticles and uses thereof | ABL1, CDKN1A, CDK2 | ABL1 1/4885BCR 173/4885KIT 246/4885 |
| US-11998548-B2 | Amorphous nilotinib microparticles and uses thereof | ABL1, CDKN1A, CDK2 | ABL1 1/4885BCR 173/4885KIT 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.